A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
Latest Information Update: 26 Jun 2025
At a glance
- Drugs Maridebart cafraglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Amgen
Most Recent Events
- 23 Jun 2025 Results from part 1 presented in the Amgen Media Release.
- 23 Jun 2025 According to American Diabetes Association media release, company presented result data from part 1 of this study at the American Diabetes Association's (ADA) 85th Scientific Sessions in Chicago and were simultaneously published in the New England Journal of Medicine (NEJM).
- 23 Jun 2025 Results presented in the American Diabetes Association media release.